Inner Banner
Dec 09-11, 2024 Paris, France

International Conference onOncology Breakthroughs

Early Bird Registration Date: Apr 23, 2024
Abstract Submission Opens: Mar 28, 2024

The International Conference on Oncology Breakthroughs, slated for December 9th to 11th, 2024, in Paris, France, is themed "Empowering Tomorrow's Cancer Care: Innovations, Collaboration, and Hope." It serves as a premier platform for global oncology leaders, researchers, clinicians, and industry experts to converge and discuss cutting-edge advancements in cancer treatment and research. With keynote speeches, panel discussions, and workshops, attendees will explore breakthroughs in cancer diagnosis, treatment modalities, and research methodologies. The conference aims to foster collaboration and interdisciplinary exchange to drive innovation in precision medicine and personalized therapies. Ethical considerations in cancer care delivery and patient-centered practices will be underscored. Paris, renowned for its cultural richness and scenic beauty, offers an inspiring backdrop for this transformative event. Networking opportunities abound, facilitating collaborations to address the global cancer burden. The conference promises to ignite hope and optimism for the future of cancer care, making Paris an apt setting for this gathering of dedicated professionals committed to advancing oncology.

Sciconx Conferences aim to bring scientists together from different fields to talk and learn from each other in both formal sessions and casual meet-ups. It's all about helping young scientists grow professionally, encouraging them to collaborate and contribute to research. By providing these opportunities, Sciconx hopes to foster a supportive environment where everyone can share ideas and make valuable connections. Ultimately, the goal is to empower emerging researchers and promote a culture of collaboration and innovation in science.

Conference Tracks

Track 1: Current Trends and Future Directions in Oncology Research

Current Trends and Future Directions in Oncology Research are shaping the landscape of cancer treatment and care. Precision medicine, targeting specific genetic mutations, is revolutionizing therapies and improving patient outcomes. Immunotherapy, harnessing the body's immune system to fight cancer, is showing remarkable efficacy across various cancer types. Advances in genomics are unraveling the molecular underpinnings of cancer, paving the way for personalized treatment approaches. Liquid biopsies offer non-invasive methods for early cancer detection and monitoring treatment response. Emerging technologies such as artificial intelligence and machine learning are aiding in data analysis and drug discovery. Combination therapies, utilizing multiple treatment modalities, are showing synergistic effects in combating resistant cancers. Collaborative research efforts are accelerating progress, with interdisciplinary approaches driving innovation. Ethical considerations regarding patient consent, privacy, and equitable access remain crucial in advancing oncology research. Overall, these trends signal a promising future where cancer treatment is increasingly effective, personalized, and accessible.

Track 2: Advancements in Cancer Immunotherapy

Advancements in Cancer Immunotherapy represent a paradigm shift in cancer treatment, harnessing the body's immune system to target and destroy cancer cells. Checkpoint inhibitors, a type of immunotherapy, have demonstrated remarkable efficacy in various cancer types, leading to durable responses and prolonged survival. CAR-T cell therapy, another groundbreaking approach, involves genetically engineering patients' own immune cells to recognize and attack cancer cells with precision. Combination immunotherapy regimens, combining different types of immunotherapies or immunotherapy with other treatments like chemotherapy or radiation, are showing synergistic effects and improving outcomes for patients. Biomarker research is helping identify patients who are most likely to benefit from immunotherapy, enabling personalized treatment approaches. Despite these advancements, challenges such as immune-related adverse events and resistance mechanisms remain areas of active research. Overall, immunotherapy represents a promising avenue in the fight against cancer, offering new hope for patients with previously untreatable malignancies.

Track 3: Precision Oncology

Precision Oncology is a groundbreaking approach to cancer treatment that tailors therapies to the unique genetic makeup of individual patients and their tumors. By analyzing the molecular characteristics of tumors, precision oncology aims to identify specific genetic mutations or alterations driving cancer growth. This enables oncologists to select targeted therapies that are most likely to be effective and minimize side effects. Advances in genomic sequencing technologies have facilitated the identification of actionable mutations, guiding treatment decisions in real time. Additionally, liquid biopsies allow for non-invasive monitoring of tumor evolution and treatment response. Precision oncology holds promise for improving patient outcomes, particularly in cancers that are traditionally difficult to treat or have developed resistance to standard therapies. However, challenges such as tumor heterogeneity and the need for access to comprehensive genomic profiling remain. Despite these challenges, precision oncology represents a paradigm shift in cancer care, offering personalized and more effective treatment options for patients.

Track 4: Targeted Therapies in Oncology

Targeted Therapies in Oncology represent a tailored approach to cancer treatment, focusing on specific molecular targets involved in cancer growth and progression. Unlike traditional chemotherapy, which affects both cancerous and healthy cells, targeted therapies aim to selectively inhibit or block the activity of proteins or pathways that drive tumor growth. These therapies can be directed towards various molecular targets, including mutated genes, overexpressed proteins, or signaling pathways essential for cancer cell survival. Examples include tyrosine kinase inhibitors, monoclonal antibodies, and hormone therapies. Targeted therapies offer several advantages, including reduced toxicity and side effects compared to conventional treatments, as well as potentially higher efficacy in patients with specific genetic alterations. However, challenges such as the development of resistance mechanisms and the need for companion diagnostic tests to identify suitable candidates remain. Overall, targeted therapies represent a significant advancement in oncology, offering more precise and personalized treatment options for cancer patients.

Track 5: Novel Biomarkers for Early Detection and Prognosis in Cancer

Novel Biomarkers for Early Detection and Prognosis in Cancer are revolutionizing the field of oncology by enabling earlier diagnosis and more accurate prediction of disease outcomes. These biomarkers can be molecules such as proteins, DNA, RNA, or even cellular characteristics that indicate the presence of cancer or its progression. Advances in genomic and proteomic technologies have led to the discovery of new biomarkers with high sensitivity and specificity for various cancer types. Liquid biopsies, which analyze circulating tumor cells or cell-free DNA in the blood, offer a non-invasive method for detecting cancer at its earliest stages and monitoring treatment response. Additionally, the development of sophisticated imaging techniques allows for the visualization of biomarkers in tumors, aiding in diagnosis and prognosis. The identification of biomarkers associated with specific tumor subtypes or treatment responses also enables personalized treatment strategies, improving patient outcomes. Despite these advancements, further research is needed to validate and optimize the clinical utility of novel biomarkers in routine cancer care. Overall, novel biomarkers hold immense promise for enhancing early detection, prognosis, and treatment of cancer, ultimately improving patient survival and quality of life.

Track 6: Genomics and Cancer

Genomics and Cancer intertwine at the forefront of cancer research, offering unprecedented insights into the genetic basis of tumorigenesis and treatment response. By analyzing the complete set of DNA within cancer cells, known as the cancer genome, researchers can identify key mutations, structural alterations, and gene expression patterns driving cancer development and progression. Genomic studies have unveiled a vast landscape of genetic alterations across different cancer types, revealing novel therapeutic targets and biomarkers for early detection and prognosis. Furthermore, advances in next-generation sequencing technologies have enabled comprehensive genomic profiling of tumors, guiding personalized treatment decisions through precision oncology approaches. The integration of genomics into clinical practice has revolutionized cancer care, facilitating the development of targeted therapies and immunotherapies tailored to individual patients' genetic profiles. Despite these advancements, challenges such as tumor heterogeneity, clonal evolution, and acquired drug resistance continue to shape the genomic landscape of cancer. Nonetheless, genomics remains a cornerstone of modern oncology, driving innovation and paving the way for more effective and personalized cancer treatments.

Track 7: Tumor Microenvironment and Cancer Progressio

The Tumor Microenvironment (TME) plays a pivotal role in cancer progression, influencing various aspects of tumor growth, invasion, metastasis, and response to therapy. Comprising cellular and non-cellular components such as immune cells, fibroblasts, blood vessels, and extracellular matrix, the TME creates a dynamic ecosystem that interacts with cancer cells in complex ways. Immune cells within the TME can either promote tumor growth (immunosuppressive) or inhibit it (immunostimulatory), depending on the balance of pro-inflammatory and anti-inflammatory signals. Additionally, stromal cells, including cancer-associated fibroblasts, contribute to tumor progression by promoting angiogenesis, remodeling the extracellular matrix, and facilitating metastasis. The TME also influences the response to cancer therapy, with immune checkpoint inhibitors targeting interactions between cancer cells and immune cells within the TME to enhance anti-tumor immune responses. Understanding the intricate interplay between cancer cells and the TME is crucial for developing novel therapeutic strategies that effectively target the tumor while minimizing off-target effects and treatment resistance. Advances in TME research hold promise for identifying new therapeutic targets and biomarkers to improve patient outcomes in cancer treatment.

Track 8: Radiation Oncology Innovations

Radiation Oncology Innovations are transforming cancer treatment, offering advanced techniques to precisely target tumors while minimizing damage to surrounding healthy tissues. Technological advancements such as intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), and stereotactic body radiation therapy (SBRT) allow for highly conformal delivery of radiation beams, improving treatment accuracy and reducing side effects. Moreover, proton therapy delivers radiation with greater precision, sparing nearby organs and tissues from unnecessary exposure. Innovations in brachytherapy, which involves placing radioactive sources directly into or near the tumor, enable higher radiation doses to be delivered locally, enhancing tumor control rates. Furthermore, the integration of artificial intelligence and machine learning algorithms into treatment planning and delivery processes optimizes treatment outcomes and efficiency. These innovations in radiation oncology are revolutionizing cancer care, offering patients safer, more effective, and personalized treatment options.

Track 9: Revolutionizing Cancer Diagnosis and Monitoring

Revolutionizing Cancer Diagnosis and Monitoring encompasses a range of cutting-edge technologies and approaches that are transforming the way we detect and track cancer progression. Liquid biopsies, for instance, analyze blood samples for circulating tumor cells, cell-free DNA, or other biomarkers, providing a non-invasive method for early cancer detection and monitoring treatment response. Imaging techniques such as positron emission tomography-computed tomography (PET-CT) and magnetic resonance imaging (MRI) offer high-resolution visualization of tumors, aiding in accurate diagnosis and staging. Additionally, advances in genomic sequencing allow for the identification of genetic mutations and molecular signatures associated with cancer, enabling more precise diagnosis and personalized treatment strategies. Moreover, wearable devices and digital health platforms enable continuous monitoring of cancer patients' physiological parameters and treatment adherence, facilitating proactive management and timely interventions. These innovations are revolutionizing cancer care by enabling earlier detection, more accurate diagnosis, and personalized monitoring, ultimately improving patient outcomes and quality of life.

Track 10: Advances in Surgical Oncology

Advances in Surgical Oncology are reshaping the landscape of cancer treatment, offering patients safer and more effective surgical options. Minimally invasive techniques such as laparoscopy and robotic-assisted surgery allow surgeons to perform complex procedures with smaller incisions, leading to reduced postoperative pain, shorter hospital stays, and faster recovery times. Moreover, image-guided surgery utilizes advanced imaging technologies like intraoperative MRI or fluorescence-guided imaging to improve surgical precision and enhance tumor removal while preserving healthy tissue. Additionally, innovations in organ preservation techniques, such as organ-sparing surgeries and limb-sparing procedures, aim to maintain functional integrity and quality of life for cancer patients. Furthermore, interdisciplinary approaches such as intraoperative radiation therapy (IORT) and hyperthermic intraperitoneal chemotherapy (HIPEC) offer targeted treatment delivery during surgery, improving local tumor control and overall survival rates. These advancements in surgical oncology are revolutionizing cancer care by optimizing treatment outcomes, reducing complications, and improving patients' overall well-being.

Track 11: Integrative Oncology

Integrative Oncology is a holistic approach to cancer care that combines conventional medical treatments with complementary therapies to address the physical, emotional, and psychological aspects of cancer. It emphasizes the importance of personalized care, focusing on enhancing quality of life, managing symptoms, and supporting overall well-being throughout the cancer journey. Integrative oncology incorporates evidence-based complementary therapies such as acupuncture, massage therapy, mind-body techniques, nutritional counseling, and exercise programs into conventional cancer treatment plans. These therapies aim to alleviate treatment-related side effects, reduce stress, improve resilience, and promote healing. Moreover, integrative oncology encourages active patient participation in decision-making and self-care practices, empowering individuals to take control of their health and improve treatment outcomes. By integrating complementary therapies with standard cancer care, integrative oncology seeks to optimize patient-centered care, enhance treatment tolerability, and improve the overall quality of life for cancer patients and survivors.

Track 12: Pediatric Oncology

Pediatric Oncology focuses on the diagnosis, treatment, and management of cancer in children and adolescents. It encompasses a multidisciplinary approach involving pediatric oncologists, hematologists, surgeons, radiation oncologists, nurses, and other healthcare professionals. Pediatric cancers differ from adult cancers in terms of their biology, treatment response, and long-term effects, necessitating specialized care tailored to the unique needs of young patients. Treatment modalities for pediatric cancers may include chemotherapy, surgery, radiation therapy, immunotherapy, and stem cell transplantation, often delivered in combination or as part of clinical trials. Due to the potential impact of cancer and its treatment on growth, development, and quality of life, pediatric oncology places a strong emphasis on supportive care, psychosocial support, and survivorship care. Advances in research have led to significant improvements in survival rates for many childhood cancers, highlighting the importance of ongoing research, advocacy, and collaboration in the field of pediatric oncology.

Track 13: Cancer Survivorship

Cancer Survivorship refers to the period after cancer treatment when a person is living with, through, and beyond cancer. It encompasses the physical, emotional, psychosocial, and economic aspects of life following cancer diagnosis and treatment. Survivorship begins at the time of diagnosis and continues throughout the rest of a person's life. Cancer survivors may face various challenges such as managing treatment side effects, addressing long-term health issues, coping with emotional distress, and navigating changes in relationships and daily life. Survivorship care plans, which outline a personalized roadmap for follow-up care, monitoring, and support, play a crucial role in helping survivors transition from active treatment to post-treatment life. Survivorship care may include regular medical check-ups, screenings for cancer recurrence or secondary cancers, referrals to specialists for ongoing issues, and interventions to address physical and emotional needs. Additionally, survivorship programs often offer resources, support groups, counseling, and wellness activities to help survivors thrive and improve their overall quality of life. By addressing the unique needs of cancer survivors, survivorship care aims to empower individuals to live well beyond cancer and embrace life to the fullest.

Track 14: Health Equity in Oncology

Health Equity in Oncology refers to the fair and just distribution of cancer prevention, diagnosis, treatment, and survivorship care across all populations, regardless of race, ethnicity, socioeconomic status, geographic location, or other factors. Disparities in cancer outcomes exist due to various social determinants of health, including access to healthcare, quality of care, environmental factors, and structural inequities. Addressing health equity in oncology involves identifying and dismantling barriers to equitable cancer care, promoting access to high-quality healthcare services, and ensuring that all individuals receive timely and appropriate cancer prevention, screening, and treatment. Strategies to achieve health equity in oncology may include increasing access to affordable healthcare coverage, expanding cancer screening and prevention programs in underserved communities, improving cultural competence and language access in healthcare settings, and implementing policies to address social determinants of health such as poverty, education, and housing. Additionally, community engagement, patient navigation programs, and partnerships with community-based organizations can play a vital role in reaching vulnerable and marginalized populations and reducing disparities in cancer outcomes. By prioritizing health equity in oncology, healthcare providers, policymakers, and stakeholders can work together to ensure that everyone has the opportunity to achieve optimal cancer prevention, treatment, and survivorship outcomes, regardless of their background or circumstances.

Track 15: Cancer Pharmacology

Cancer Pharmacology is the study of drugs and medications used in the prevention, treatment, and management of cancer. It encompasses a wide range of therapeutic agents, including chemotherapy drugs, targeted therapies, immunotherapies, hormonal therapies, and supportive care medications. Chemotherapy drugs work by killing rapidly dividing cancer cells, while targeted therapies specifically target molecular pathways or cellular processes involved in cancer growth and progression. Immunotherapies harness the body's immune system to recognize and attack cancer cells, while hormonal therapies block the effects of hormones that promote cancer growth. Supportive care medications help manage treatment side effects, such as nausea, pain, and fatigue, and improve patient's quality of life during cancer treatment. Cancer pharmacology also involves understanding drug mechanisms of action, pharmacokinetics, pharmacodynamics, drug interactions, and adverse effects to optimize treatment outcomes and minimize toxicity. Additionally, pharmacogenomics, which studies how an individual's genetic makeup affects their response to medications, plays a crucial role in personalized cancer treatment. By advancing our understanding of cancer biology and drug development, cancer pharmacology continues to drive innovation in cancer care, leading to the development of new and more effective treatments for cancer patients.

Track 16: Artificial Intelligence and Machine Learning in Oncology

Artificial Intelligence (AI) and Machine Learning (ML) are revolutionizing oncology by analyzing complex data to enhance cancer diagnosis, treatment, and patient care. In medical imaging analysis, AI algorithms accurately detect and characterize tumors from radiological images, enabling earlier diagnosis and treatment planning. Genomic data analysis with AI identifies genetic mutations and biomarkers, guiding personalized treatment strategies for individual patients. Predictive modeling assists in forecasting cancer risk, treatment response, and patient outcomes based on clinical and molecular data. AI-driven drug discovery accelerates the identification of potential drug candidates and optimizes the development of novel therapies for cancer treatment. Decision support systems integrate clinical data to generate personalized treatment recommendations, aiding oncologists in treatment planning. Overall, AI and ML hold immense promise in transforming oncology practice, improving diagnostic accuracy, treatment selection, and patient outcomes in the fight against cancer.

Track 17: Clinical Trials and Translational Research

Clinical Trials and Translational Research are pivotal in advancing cancer treatment and care by evaluating new therapies and translating scientific discoveries into clinical practice. These trials investigate novel drugs, treatment combinations, and innovative approaches to improve patient outcomes. Translational research bridges the gap between laboratory findings and real-world applications, facilitating the development of personalized cancer treatments. Clinical trials provide crucial evidence for the approval of new treatments and contribute to expanding treatment options for patients. Additionally, they identify biomarkers predictive of treatment response and resistance, informing personalized treatment strategies. Translational research accelerates the translation of scientific discoveries into clinical practice, fostering the development of precision medicine approaches. Overall, clinical trials and translational research play vital roles in driving innovation and improving outcomes for cancer patients.

Track 18: Ethical Considerations in Oncology Research and Clinical Practice

Ethical considerations in oncology research and clinical practice are essential for safeguarding patient rights and well-being. In research, obtaining informed consent and ensuring confidentiality are paramount to protecting participants' autonomy and privacy. Rigorous ethical review by institutional review boards (IRBs) is necessary to uphold ethical standards and minimize potential harm to participants. In clinical practice, oncologists must prioritize patient autonomy and involve patients in treatment decisions through shared decision-making. Equity in access to cancer care and clinical trials is crucial to promote fairness and justice in healthcare delivery. Efforts to address disparities in access to care, such as socioeconomic barriers and structural inequities, are essential for achieving health equity in oncology. Overall, ethical considerations are fundamental to upholding the highest standards of patient care and research integrity in oncology.

Track 19: Global Collaborations in Oncology

Global collaborations in oncology are pivotal for advancing cancer research, treatment, and care on a global scale. These collaborations bring together researchers, clinicians, policymakers, and healthcare organizations from around the world to share knowledge, expertise, and resources. By pooling diverse perspectives and resources, global collaborations accelerate scientific discoveries, promote innovation, and address common challenges in cancer prevention, diagnosis, and treatment. International research partnerships facilitate the exchange of data, samples, and best practices, enabling researchers to conduct large-scale studies and identify global patterns of cancer incidence, prevalence, and outcomes. Additionally, global collaborations foster capacity-building initiatives, training programs, and technology transfer efforts to strengthen healthcare systems and build local expertise in cancer care. Ultimately, global collaborations in oncology aim to reduce the global burden of cancer, improve patient outcomes, and promote health equity worldwide.

Track 20: Cancer Prevention and Screening

Cancer prevention and screening are integral components of public health initiatives aimed at reducing the burden of cancer worldwide. Prevention strategies emphasize lifestyle modifications, including maintaining a healthy diet, regular exercise, and avoiding tobacco and excessive alcohol consumption. Screening programs involve various tests designed to detect cancer early, such as mammograms for breast cancer, Pap smears for cervical cancer, and colonoscopies for colorectal cancer. Additionally, vaccinations against viruses like HPV and hepatitis B can prevent infections associated with certain cancers. Sun safety practices, genetic counseling, and environmental awareness also contribute to cancer prevention efforts. Community education and outreach programs are essential for raising awareness about prevention and screening methods, empowering individuals to recognize early warning signs, and seek timely medical attention. Ultimately, collaboration between healthcare providers, policymakers, and communities is crucial for implementing effective cancer prevention and screening initiatives globally, leading to improved outcomes and reduced mortality rates.

Relevant Conferences: Cancer meetingsOncology conferencesCancer research conferencesTumor biology conferences | Cancer therapy conferences | Cancer science conferences | Cancer symposiums | Cancer workshops | Cancer forumsCancer congress | Cancer summitsCancer seminars | Cancer retreats | Cancer events Tumor conferencesOncology symposiums | Tumor biology meetings | Cancer therapy meetings | Cancer science meetings | Cancer Congress | Congress of Radiology | Radiology colloquium | Radiology forum | Radiology workshopTumor colloquiums | Radiology seminar


SciconX, Kings Houxse,
17 Soho Square London W1D 3QJ,
United Kingdom


+44 330 808 1939